The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.
 
Dharmesh Gopalakrishnan
No Relationships to Disclose
 
Katharine Collier
Research Funding - Conquer Cancer Foundation
 
Joseph J Park
No Relationships to Disclose
 
Jacob P Zaemes
No Relationships to Disclose
 
Elaine Tat Lam
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Immunomedics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Decibel Therapeutics
 
Sabah Alaklabi
No Relationships to Disclose
 
Ellen Jaeger
No Relationships to Disclose
 
Rahul Atul Parikh
Stock and Other Ownership Interests - Myovant Sciences (I)
Consulting or Advisory Role - Merck
Research Funding - Saladax Biomedical; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; BMS; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Research Funding - Blue Earth Diagnostics (Inst)
 
Eric Kauffman
No Relationships to Disclose
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Arrowhead Pharmaceuticals; AstraZeneca; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; Idera; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Scholar Rock; Seagen; Surface Oncology; Third Rock Ventures; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck
 
Yuanquan Yang
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Pfizer
 
Saby George
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Merck; Pfizer; QED Therapeutics; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst)